



Michigan-Based CRO MIR Preclinical Services to Acquire Gamma Medica's New X-PET(TM) Pre-Clinical Imaging System

[Market Wire](#), [December, 2004](#)

MIR Preclinical Services (MIR), a contract research organization (CRO) located in Ann Arbor, Michigan, will take delivery of a Gamma Medica X-PET(TM) pre-clinical imaging system in early 2005.

Dr. Wilbur Leopold, president of MIR, expects to use the Gamma Medica system to offer pre-clinical PET imaging services in early 2005. "Demand for pre-clinical imaging is increasing rapidly, largely due to innovations like the X-PET, that enable routine clinical protocols to be used efficiently at the pre-clinical level," said Dr. Leopold. "As a contract research organization, MIR is delighted to be able to offer state-of-the-art pre-clinical PET imaging to clients, and play an increasingly widespread role in the development of new cancer therapies."

MIR is a CRO specializing in the pre-clinical evaluation of novel anti-tumor agents. The company boasts management with over 80 years of major pharma cancer drug discovery experience, and is a leader in the integration of traditional anti-cancer efficacy testing with clinically relevant imaging services to provide new insights to drug discovery and development. MIR offers a wide array of tumor models including human tumor xenografts, syngeneic, and transgenic tumor models. The company is unique in its ability to apply state-of-the-art non-invasive imaging modalities including magnetic resonance imaging (MRI), X-ray micro-CT and soon, PET to visualize biological processes such as signal transduction, apoptosis and angiogenesis. MIR's mission is to non-invasively provide its clients with an integrated correlation of efficacy with pharmacodynamics (mechanism of action) directly applicable to clinical trials. More information about MIR can be found at www.molecularimaging.com.

X-PET is the newest addition to Gamma Medica's FLEX(TM) platform of pre-clinical imaging systems. The FLEX platform also includes the

X-O(TM) micro CT system and the X-SPECT® MicroSPECT® system. FLEX is the first platform in either the pre-clinical or clinical arena to provide co-linear tri-modality imaging, allowing a stationary subject to be imaged by up to three different imaging systems. All the FLEX imaging systems share a common gantry, allowing highly accurate co-registration and fusion of the various image data. Additionally, FLEX is modular, reconfigurable, upgradeable, and expandable so that researchers can configure the product with the modalities they need, individually, or in combinations of two, or even all three in a single instrument. These features make FLEX the most cost-effective and high productivity instrument in multi-modality pre-clinical imaging.

"We are very gratified that MIR Preclinical Services chose our X-PET system and our FLEX platform," said Gamma Medica Senior Vice President David Wilk. "Our X-PET is a world-class pre-clinical PET system, and the FLEX platform can easily be configured to add additional modalities, such as CT. FLEX gives MIR the ability to add new sub-systems and modalities as its needs grow."

Gamma Medica, Inc., Northridge, CA, designs, develops and manufactures next-generation imaging systems for both clinical and pre-clinical applications. The company invented MicroSPECT, and its X-SPECT system is the market leader in the small animal SPECT category. Gamma Medica's X-PET(TM) system has the highest sensitivity and largest axial field of view among small animal PET systems. The company's X-O(TM) system is a standalone Micro CT device that can perform full body scans on a wide range of test subjects in under one minute, making it one of the fastest such systems in the industry. All three systems share a common gantry and are part of the company's FLEX platform of pre-clinical imaging systems. Any two systems can be combined in the common gantry, as can all three. Gamma Medica pre-clinical imaging systems are used by medical researchers and drug companies that use in-vivo imaging techniques and molecular markers to dramatically speed up studies of disease progression and therapy. More information can be found by visiting www.gammamedica.com.